FluoroPharma Medical, Inc. (FPMI)

[MissionIR]

FPMI Announces Appointment to Board of Directors

FluoroPharma Medical, a biopharmaceutical company providing proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels, announced that it has appointed Lawrence Atinsky to its Board of Directors. The appointment is effective January 3, 2012.

Mr. Atinsky has worked closely with a number of biotechnology companies over the past ten years, helping them execute their strategic growth plans, and is currently a partner at Ascent Biomedical Ventures. Ascent is a venture capital firm targeting early stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. Prior to joining Ascent, Mr. Atinsky was an attorney at Skadden Arps where he specialized in mergers and acquisitions.

FluoroPharma President and CEO, Thijs Spoor, commented on the appointment: “I am delighted to welcome Lawrence to the FluoroPharma Board. His legal background, along with his extensive biotech business experience, brings invaluable knowledge and will complement the considerable expertise of the Board.”

FluoroPharma’s focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease. The goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management, and better patient outcomes. The company is currently advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer’s disease, and agents that could potentially be used for imaging specific cancers.